Cencora, Inc. Files 2024 10-K Report

Ticker: COR · Form: 10-K · Filed: Nov 26, 2024 · CIK: 1140859

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

TL;DR

Cencora (formerly AmerisourceBergen) dropped its 2024 10-K. All systems go.

AI Summary

Cencora, Inc. (formerly AmerisourceBergen Corp) filed its 2024 10-K report for the fiscal year ending September 30, 2024. The company, a wholesale distributor of drugs and sundries, is incorporated in Delaware and headquartered in Conshohocken, PA. The filing covers financial performance and business operations for the period, with previous financial years also detailed.

Why It Matters

This 10-K filing provides a comprehensive overview of Cencora's financial health and strategic direction for investors and stakeholders, impacting decisions related to the company's stock and future performance.

Risk Assessment

Risk Level: medium — As a large, publicly traded company in the pharmaceutical supply chain, Cencora faces inherent risks related to regulatory changes, competition, and economic fluctuations.

Key Numbers

Key Players & Entities

FAQ

What were Cencora's total revenues for the fiscal year ending September 30, 2024?

The provided text does not contain specific revenue figures for the fiscal year ending September 30, 2024. A full review of the 10-K document would be required to ascertain this information.

What is Cencora's primary business activity?

Cencora, Inc. is primarily involved in the wholesale distribution of drugs, proprietaries, and druggists' sundries, as indicated by its SIC code 5122.

When did AmerisourceBergen Corp change its name to Cencora, Inc.?

The name change from AmerisourceBergen Corp to Cencora, Inc. occurred on May 17, 2001.

In which state is Cencora, Inc. incorporated?

Cencora, Inc. is incorporated in Delaware (DE).

What is the SEC file number for Cencora, Inc.'s 10-K filing?

The SEC file number for this 10-K filing is 001-16671.

Filing Stats: 4,136 words · 17 min read · ~14 pages · Grade level 16.5 · Accepted 2024-11-26 14:45:55

Key Financial Figures

Filing Documents

Signatures

Signatures 90 Table of Contents Cautionary Note Regarding Forward-Looking Statements This Annual Report on Form 10-K contains " forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act") . These forward-looking statements may include, without limitation, statements regarding our financial position, business strategy and the plans and objectives of management for our future operations; future liabilities and other obligations; anticipated trends and prospects in the industries in which our business operates; new products, services and related strategies; and capital allocation, including share repurchases and dividends. These statements may constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this Annual Report on Form 10-K, words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "might," "on track," "opportunity," "plan," "possible," "potential," "predict," "project," "seek," "should," "strive," "sustain," "synergy," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements reflect management's current views with respect to future events, subject to uncertainty and changes in circumstances, and are based on assumptions as of the date of this Annual Report on Form 10-K. Although we believe that the assumptions underlying the forward-looking statements are reasonable, we can give no assurance that our expectations will be attained. Factors that could have a material adverse effect on our financial condition, liquidity, results of

BUSINESS

ITEM 1. BUSINESS As used herein, the terms "Company," "Cencora," "we," "us," or "our" refer to Cencora, Inc., a Delaware corporation. Cencora is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. More specifically, we distribute a comprehensive offering of brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers located in the United States and select global markets, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, veterinarians, and other customers. Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services, including data analytics, outcomes research, reimbursement and pharmaceutical consulting services (including regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance) niche premium logistics services, inventory management, pharmacy automation, pharmacy management, and packaging solutions. References to "fiscal 2024," "fiscal 2023," and "fiscal 2022" refer to the fiscal years ended September 30, 2024, 2023, and 2022, respectively. Industry Overview Pharmaceutical sales in the United States, as recently estimated by IQVIA, an independent third-party provider of information to the pharmaceutical and healthcare industry, are expected to grow at a compound annual growth rate of app

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing